New antibody drug takes aim at Hard-to-Treat cancers

NCT ID NCT07606612

Recruiting now Disease control Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase trial tests a new drug called SI-B036, a bispecific antibody, in 31 adults with advanced solid tumors that have spread. The main goals are to check safety, find the right dose, and see early signs of tumor shrinkage. Participants receive the drug by IV every 3 weeks.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: SI-B036 bispecific antibody
What this could lead to: If it works, this could point toward a new treatment option for advanced solid tumors that are hard to treat.
What could go wrong: This is a very early Phase 1 trial with only 31 people, so it is mainly checking safety and dosing. The drug may not shrink tumors or could cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SOLID TUMOR

Contacts and locations

Locations

Sun Yat-sen University Cancer Center
RECRUITING

Guangzhou, Guangdong, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.